Prescott Group Capital Management L.L.C. grew its position in shares of The Beauty Health Company (NASDAQ:SKIN - Free Report) by 47.0% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 646,798 shares of the company's stock after buying an additional 206,798 shares during the period. Prescott Group Capital Management L.L.C. owned about 0.52% of Beauty Health worth $867,000 as of its most recent SEC filing.
A number of other large investors also recently bought and sold shares of the company. ProShare Advisors LLC lifted its holdings in Beauty Health by 49.0% during the 4th quarter. ProShare Advisors LLC now owns 20,959 shares of the company's stock worth $33,000 after buying an additional 6,896 shares during the last quarter. Barclays PLC lifted its holdings in Beauty Health by 11.1% during the 4th quarter. Barclays PLC now owns 117,920 shares of the company's stock worth $187,000 after buying an additional 11,817 shares during the last quarter. Raymond James Financial Inc. bought a new position in Beauty Health during the 4th quarter worth approximately $25,000. Price T Rowe Associates Inc. MD lifted its holdings in Beauty Health by 19.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 114,147 shares of the company's stock worth $182,000 after buying an additional 18,400 shares during the last quarter. Finally, Bank of Montreal Can lifted its holdings in Beauty Health by 32.6% during the 4th quarter. Bank of Montreal Can now owns 113,096 shares of the company's stock worth $180,000 after buying an additional 27,791 shares during the last quarter. Institutional investors own 93.26% of the company's stock.
Beauty Health Stock Down 9.4%
Shares of Beauty Health stock opened at $1.83 on Friday. The company has a current ratio of 7.47, a quick ratio of 6.43 and a debt-to-equity ratio of 12.01. The business's 50 day simple moving average is $1.77 and its 200-day simple moving average is $1.52. The stock has a market capitalization of $230.56 million, a price-to-earnings ratio of -4.46 and a beta of 1.22. The Beauty Health Company has a twelve month low of $0.78 and a twelve month high of $2.38.
Beauty Health (NASDAQ:SKIN - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.13) by $0.05. The business had revenue of $69.60 million for the quarter, compared to analysts' expectations of $63.88 million. Beauty Health had a negative return on equity of 67.91% and a negative net margin of 11.94%. Equities research analysts forecast that The Beauty Health Company will post -0.25 earnings per share for the current year.
Analysts Set New Price Targets
Separately, Canaccord Genuity Group reduced their target price on Beauty Health from $1.50 to $1.25 and set a "hold" rating on the stock in a report on Monday, May 5th.
Read Our Latest Report on SKIN
Beauty Health Profile
(
Free Report)
The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Beauty Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beauty Health wasn't on the list.
While Beauty Health currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.